Наследственная форма рака молочной железы: современное состояние проблемы

Обложка

Цитировать

Полный текст

Аннотация

Показатели заболеваемости раком молочной железы растут в большинстве стран год от года. Цель настоящего обзора литературы — представить современные сведения о причинах, механизмах развития, различных методах профилактики, ранней диагностики и лечения наследственной формы рака молочной железы. Рассматривается эффективность двусторонней профилактической мастэктомии.

Об авторах

Фатима Сослановна Гатуева

Республиканский онкологический диспансер

Автор, ответственный за переписку.
Email: ledoffcomp@ro.ru

врач-онколог 3-го хирургического отделения

Россия, Владикавказ, Республика Северная Осетия-Алания

Людмила Николаевна Любченко

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина»

Email: clingen@mail.ru
SPIN-код: 9589-9057

д.м.н., заведующая лабораторией клинической онкогенетики

Россия, Москва

Сергей Евгеньевич Малыгин

Российский национальный исследовательский медицинский университет имени Н.И. Пирогова

Email: drmalygin@mail.ru
SPIN-код: 7066-0295

к.м.н., доцент кафедры онкологии и лучевой терапии

Россия, Москва

Список литературы

  1. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность) / Под ред. Каприна А.Д., Старинского В.В., Петровой Г.В. — М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИРЦ» Минздрава России, 2018. — 250 с. [Zlokachestvennye novoobrazovaniya v Rossii v 2016 godu (zabolevaemost’ i smertnost’). Ed by Kaprin A.D., Starinskii V.V., Petrova G.V. Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMIRTs» Minzdrava Rossii; 2018. 250 p. (In Russ).]
  2. Kuusisto KM, Bebel A, Vihinen M, et al. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50 and CDH1 mutations in high-risk finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res. 2011;13(1):R20. doi: 10.1186/bcr2832.
  3. Peng L, Xu T, Long T, Zuo H. Association between BRCA status and P53 status in breast cancer: a meta-analysis. Med Sci Monit. 2016;22:1939–1945. doi: 10.12659/msm.896260.
  4. Janavičius R. Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J. 2010;1(3):397–412. doi: 10.1007/s13167-010-0037-y.
  5. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–1130. doi: 10.1086/375033.
  6. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98(23):1694–1706. doi: 10.1093/jnci/djj465.
  7. Litton JK, Ready K, Chen H, et al. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer. 2012;118(2):321–325. doi: 10.1002/cncr.26284.
  8. Bayraktar S, Amendola L, Gutierrez-Barrera AM, et al. Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. Breast. 2014;23(6):770–774. doi: 10.1016/j.breast.2014.08.010.
  9. Kim JY, Moon HG, Kang YJ, et al. The effect of reproductive factors on breast cancer presentation in women who are BRCA mutation carrier. J Breast Cancer. 2017;20(3):279–285. doi: 10.4048/jbc.2017.20.3.279.
  10. Cullinane CA, Lubinski J, Neuhausen SL, et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 2005;117(6):988–991. doi: 10.1002/ijc.21273.
  11. Alsaker MD, Opdahl S, Romundstad PR, Vatten LJ. Association of time since last birth, age at first birth and parity with breast cancer survival among parous women: a register-based study from Norway. Int J Cancer. 2013;132(1):174–181. doi: 10.1002/ijc.27593.
  12. Andrieu N, Goldgar DE, Easton DF, et al.; IBCCS Collaborators Group. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst. 2006;98(8):535–544. doi: 10.1093/jnci/djj132.
  13. Milne RL, Osorio A, Ramóny Cajal T, et al. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2010;119(1):221–232. doi: 10.1007/s10549-009-0394-1.
  14. Kotsopoulos J, Lubinski J, Salmena L. Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2012;14(2):R42. doi: 10.1186/bcr3138.
  15. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating. J Clin Oncol. 2007;25(25):3831–3836. doi: 10.1200/JCO.2007.11.1179.
  16. Gronwald J, Byrski T, Huzarski T, et al. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat. 2006;95(2):105–109. doi: 10.1007/s10549-005-9051-5.
  17. Lee E, Ma H, McKean-Cowdin R, et al. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3170–3178. doi: 10.1158/1055-9965.EPI-08-0396.
  18. Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju091. doi: 10.1093/jnci/dju091.
  19. Fischer C, Kuchenbäcker K, Engel C, et al. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium German Consortium for Hereditary Breast and Ovarian Cancer. J Med Genet. 2013;50(6):360–367. doi: 10.1136/jmedgenet-2012-101415.
  20. Rosner BA, Colditz GA, Hankinson SE, et al. Validation of Rosner-Colditz breast cancer incidence model using an independent data set, the California Teachers Study. Breast Cancer Res Treat. 2013;142(1):187–202. doi: 10.1007/s10549-013-2719-3.
  21. Evans DG, Ingham S, Dawe S, et al. Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme. Fam Cancer. 2014;13(2):189–196. doi: 10.1007/s10689-013-9694-z.
  22. Zeichner SB, Stanislaw C, Meisel JL. Prevention and screening in hereditary breast and ovarian cancer. Oncology (Williston Park). 2016;30(10):896–904.
  23. Dontu G, El-Ashry D, Wicha MS. Breast cancer/stem progenitor cells and estrogen receptor. Trends Endocrinol Metab. 2004;15(5):193–197. doi: 10.1016/j.tem.2004.05.011.
  24. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–1948. doi: 10.1056/NEJMra1001389.
  25. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25(43):5846–5853. doi: 10.1038/sj.onc.1209876.
  26. Daly MB, Pilarski R, Axilbund JE, et al. Genetic/familial high-risk assessment: breast and ovarian, version 2.2015. J Natl Compr Canc Netw. 2016;14(2):153–162. doi: 10.6004/jnccn.2016.0018.
  27. Honrado E., Benítez J, Palacios J. Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit Rev Oncol Hematol. 2006;59(1):27–39. doi: 10.1016/j.critrevonc.2006.01.006.
  28. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055–1062. doi: 10.1200/JCO.2004.04.188.
  29. Jansen-van der Weide MC, Greuter MJ, Jansen L, et al. Exposure to low-dose radiation and the risk of breast cancer among women with a familial or genetic predisposition: a meta-analysis. Eur Radiol. 2010;20(11):2547–2556. doi: 10.1007/s00330-010-1839-y.
  30. Pijpe A, Andrieu N, Easton DF, et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ. 2012;345:e5660. doi: 10.1136/bmj.e5660.
  31. Heisey R, Carroll JC. Identification and management of women with a family history of breast cancer: practical guide for clinicians. Can Fam Physician. 2016;62(10):799–803.
  32. Freitas V, Crystal P, Kulkarni SR, et al. The value of breast MRI in high-risk patients with newly diagnosed breast cancer to exclude invasive disease in the contralateral prophylactic mastectomy: is there a role to choose wisely patients for sentinel node biopsy? Cancer Med. 2016;5(6):1031–1036. doi: 10.1002/cam4.663.
  33. Passaperuma K, Warner E, Causer PA, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutation. Br J Cancer. 2012;107(1):24–30. doi: 10.1038/bjc.2012.204.
  34. Kurian AW, Sigal BM, Plevritis SK. Plevritis plevritis survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2010;28(2):222–231. doi: 10.1200/JCO.2009.22.7991.
  35. Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118(9):2281–2284. doi: 10.1002/ijc.21536.
  36. Vogel VG. Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women. Breast Cancer (Dove Med Press). 2011;3:127–137. doi: 10.2147/BCTT.S11288.
  37. Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014;144(3):443–455. doi: 10.1007/s10549-014-2890-1.
  38. Garcia-Etienne CA, Barile M, Gentilini OD, et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol. 2009;16(12):3380–3387. doi: 10.1245/s10434-009-0638-7.
  39. Goodwin PJ, Phillips KA, West DW, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol. 2012;30(1):19–26. doi: 10.1200/JCO.2010.33.0068.
  40. Manning AT, Sacchini VS. Conservative mastectomies for breast cancer and risk-reducing surgery: the Memorial Sloan Kettering Cancer Center experience. Gland Surg. 2016;5(1):55–62. doi: 10.3978/j.issn.2227-684X.2015.10.02.
  41. Murthy V, Chamberlain RS. Defining a place for nipple sparcing mastectomy in modern breast care: an evidence based review. Breast J. 2013;19(6):571–581. doi: 10.1111/j.1524-4741.2011.01220.x.
  42. Peled AW, Wang F, Foster RD, et al. Expanding the Indications for total skin-sparing mastectomy: is it safe for patients with locally advanced disease? Ann Surg Oncol. 2016;23(1):87–91. doi: 10.1245/s10434-015-4734-6.
  43. Phillips KA, Milne RL, Rookus MA, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutations. J Clin Oncol. 2013;31(25):3091–3099. doi: 10.1200/JCO.2012.47.8313.
  44. Metcalfe KA, Lubinski J, Ghadirian P, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008;26(7):1093–1097. doi: 10.1200/JCO.2007.12.6078.
  45. McLaughlin CC, Lillquist PP, Edge SB Surveillance of prophylactic mastectomy: trends in use from 1995 through 2005. Cancer. 2009 Dec 1; 115(23):5404-12.
  46. King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29(16):2158–2164. doi: 10.1200/JCO.2010.29.4041.
  47. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159–164. doi: 10.1056/NEJM200107193450301.
  48. Fu Y, Zhuang Z, Dewing M, et al. Predictors for contralateral prophylactic mastectomy in breast cancer patients. Int J Clin Exp Pathol. 2015;8(4):3748–3764.
  49. Yao K, Liederbach E, Tang R, et al. Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature. Ann Surg Oncol. 2015;22(2):370–376. doi: 10.1245/s10434-014-3883-3.
  50. Van Verschuer VM, Maijers MC, van Deurzen CH, Koppert LB. Oncological safety of prophylactic breast surgery: skin-sparing and nipple-sparing versus total mastectomy. Gland Surg. 2015;4(6):467–475. doi: 10.3978/j.issn.2227-684X.2015.02.01.
  51. Griepsma M, de Roy van Zuidewijn DB, Grond AJ, et al. Residual breast tissue after mastectomy: how often and where is it located? Ann Surg Oncol. 2014;21(4):1260–1266. doi: 10.1245/s10434-013-3383-x.
  52. Benson JR, Dumitru D, Malata CM. Oncologic safety of conservative mastectomy in the therapeutic setting. Gland Surg. 2016;5(1):37–46. doi: 10.3978/j.issn.2227-684X.2015.05.13.
  53. Портной С.М., Любченко С.Н., Блохин В.А., и др. Профилактика BRCA-ассоциированных рака молочной железы и рака яичников. Обзор литературы и собственные данные // Онкогинекология. — 2012. — №1. — С. 68–72. [Portnoy SM, Lubchenko LN, Blochin SN, et al. Prophylactic of BRCA1, 2-associated breast and ovarian cancers. Onkoginekologiia. 2012;(1):68–72. (In Russ).]
  54. Pinell-White XA, Kolegraff K, Carlson GW. Predictors of contralateral prophylactic mastectomy and the impact on breast reconstruction. Ann Plast Surg. 2014;72(6):S153–157. doi: 10.1097/SAP.0000000000000099.
  55. Albornoz CR, Bach PB, Mehrara BJ, et al. A paradigm shift in U.S. Breast reconstruction: increasing implant rates. Plast Reconstr Surg. 2013;131(1):15–23. doi: 10.1097/PRS.0b013e3182729cde.
  56. Geiger AM, West CN, Nekhlyudov L, et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol. 2006;24(9):1350–1356. doi: 10.1200/JCO.2005.01.9901.
  57. Hwang ES, Locklear TD, Rushing CN, et al. Patient-reported outcomes after choice for contralateral prophylactic mastectomy. Clin Oncol. 2016;34(13):1518–1527. doi: 10.1200/JCO.2015.61.5427.
  58. Koslow S, Pharmer LA, Scott AM, et al. Long-term patient-reported satisfaction after contralateral prophylactic mastectomy and implant reconstruction. Ann Surg Oncol. 2013;20(11):3422–3429. doi: 10.1245/s10434-013-3026-2.
  59. Tondu T, Thiessen F, Tjalma WA. Prophylactic bilateral nipple-sparing mastectomy and a staged breast reconstruction technique: preliminary results. Breast Cancer (Auckl). 2016;10:185–189. doi: 10.4137/BCBCR.S40033.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Гатуева Ф.С., Любченко Л.Н., Малыгин С.Е., 2020

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах